Semaglutide 2.4mg (GLP-1 Agonist): Proven GLP-1 effects (appetite suppression, gastric emptying) Already FDA-approved as Wegovy Established safety profile Cagrilintide 2.4mg (Amylin Analog): Mimics amylin, a hormone co-secreted with insulin Slows gastric emptying through different pathway than GLP-1 Reduces appetite through hindbrain (not hypothalamus) Improves postprandial glucose The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects
Journal of Neurotrauma, 27(5), 897-907
Zemek F, Drtinova L, Nepovimova E, Sepsova V, Korabecny J, Klimes J, et al
No part of this description should be interpreted as suggesting human use, animal use, cosmetic outcomes, skin-related outcomes, anti-aging outcomes, treatment outcomes, prevention outcomes, recovery, diagnosis, cure, or personal application
Specifically, IL-1 is constitutively produced and retained in keratinocytes, but in response to several stimuli, IL-1 is released, which is essentially a primary event of inflammation